Abeona Therapeutics (NASDAQ:ABEO) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Abeona Therapeutics (NASDAQ:ABEO) from a sell rating to a hold rating in a research note released on Tuesday.

A number of other equities research analysts have also weighed in on the company. HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of Abeona Therapeutics in a research report on Monday, November 25th. Cantor Fitzgerald restated an “overweight” rating and set a $18.00 price target on shares of Abeona Therapeutics in a report on Tuesday, October 29th.

Abeona Therapeutics Stock Performance

Shares of Abeona Therapeutics stock opened at $5.91 on Tuesday. The company’s 50 day moving average price is $6.01 and its two-hundred day moving average price is $5.59. The firm has a market capitalization of $256.91 million, a P/E ratio of -2.20 and a beta of 1.44. Abeona Therapeutics has a fifty-two week low of $3.05 and a fifty-two week high of $9.01. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12.

Institutional Investors Weigh In On Abeona Therapeutics

Institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC lifted its position in shares of Abeona Therapeutics by 581.6% in the 2nd quarter. Renaissance Technologies LLC now owns 503,293 shares of the biopharmaceutical company’s stock worth $2,134,000 after purchasing an additional 429,456 shares during the period. Simplify Asset Management Inc. bought a new position in Abeona Therapeutics during the second quarter worth $1,732,000. abrdn plc lifted its holdings in Abeona Therapeutics by 158.8% in the third quarter. abrdn plc now owns 326,995 shares of the biopharmaceutical company’s stock valued at $2,067,000 after buying an additional 200,647 shares during the period. Western Standard LLC boosted its position in Abeona Therapeutics by 7.0% during the third quarter. Western Standard LLC now owns 1,698,097 shares of the biopharmaceutical company’s stock valued at $10,732,000 after acquiring an additional 110,998 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in Abeona Therapeutics by 21.7% during the 3rd quarter. Geode Capital Management LLC now owns 465,317 shares of the biopharmaceutical company’s stock worth $2,942,000 after acquiring an additional 83,050 shares during the period. Institutional investors own 80.56% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.